- Home
- JAZZ vs ARE Comparison
JAZZ vs ARE Comparison
Compare JAZZ & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | ARE |
|---|---|---|
| Founded | 2003 | 1994 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.1B |
| IPO Year | 2007 | 1997 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | ARE |
|---|---|---|
| Price | $180.50 | $48.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 11 |
| Target Price | ★ $215.92 | $58.11 |
| AVG Volume (30 Days) | 966.4K | ★ 1.7M |
| Earning Date | 05-05-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 9.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,618,693,000.00 | ★ $3,026,556,000.00 |
| Revenue This Year | $6.17 | N/A |
| Revenue Next Year | $7.66 | $0.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $95.49 | $44.10 |
| 52 Week High | $198.00 | $98.27 |
Technical Indicators
Market Signals| Indicator | JAZZ | ARE |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 36.25 |
| Support Level | $176.67 | $44.10 |
| Resistance Level | $182.99 | $49.17 |
| Average True Range (ATR) | 4.97 | 1.79 |
| MACD | -1.09 | -0.37 |
| Stochastic Oscillator | 25.88 | 6.42 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.